nach oben

Erschienen in:

01.11.2006 | Hepatobiliary-Pancreas

Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?

verfasst von: R. Vilana, L. Bianchi, M. Varela, C. Nicolau, M. Sánchez, C. Ayuso, M. García, M. Sala, J. M. Llovet, J. Bruix, C. Bru, BCLC Group

Erschienen in: European Radiology | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to assess the efficacy of contrast-enhanced ultrasonography (CEUS) with SonoVue ^R to evaluate the response to percutaneous treatment (ethanol injection/radiofrequency) of hepatocellular carcinoma in comparison with spiral computed tomography (CT) immediately and 1 month after treatment. Forty-one consecutive cirrhotic patients with early stage tumor (not suitable for resection) were included. Spiral CT and CEUS were performed in all patients before treatment, in the following 24 h, and 1 month later. The results of each examination were compared with the 1-month spiral CT, considered the gold standard technique. The 24-h CEUS and the 24-h spiral CT sensitivity to detect residual disease were 27% and 20%, respectively. The 24-h CEUS and the 24-h spiral CT positive predictive value of persistent vascularization detection were 75% and 66%, respectively. The 1-month CEUS detected partial responses in ten out of 11 cases (91% sensitivity, 97% specificity, 95% accuracy). Spiral CT and CEUS performed in the 24 h following treatment are slightly useful to evaluate therapeutic efficacy. The 1-month CEUS has a high diagnostic accuracy compared with spiral -CT in the usual assessment of percutaneous treatment response.

Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: globocan 2000. Int J Cancer 94:153–156PubMedCrossRef

Sangiovanni A, Del Ninno E, Fasani P et al (2004) Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126(4):1005–1014PubMedCrossRef

Benvegnu L, Gios M, Boccato S, Alberti A (2004) Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53:744–749PubMedCrossRef

Bruix J, Sherman M, Llovet JM et al (2001) Clinical Management of Hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol 35:421–430PubMedCrossRef

Bartolozzi C, Lencioni R, Ricci P, Paolicchi A, Rossi P, Passariello R (1998) Hepatocellular carcinoma. Treatment with percutaneous ethanol injection. Evaluation with contrast enhanced color Doppler US. Radiology 209:387–393PubMed

Choi D, Lim HK, Kim SH et al (2000) Hepatocellular carcinoma treated with percutaneous radiofrequency ablation: usefulness of power Doppler US with a microbubble contrast agent in evaluating therapeutic response. Preliminary results. Radiology 217:558–563PubMed

Ding H, Kudo M, Onda H, Suetomi Y, Minami Y, Maekawa K (2001) Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma. AJR Am J Roentgenol 176:661–666PubMed

Meloni MF, Goldberg SN, Livraghi T et al (2001) Hepatocellular carcinoma treated with radiofrequency ablation: comparison of pulse inversion contrast-enhanced harmonic sonography, contrast-enhanced power Doppler sonography, and helical CT. AJR Am J Roentgenol 177:375–380PubMed

Cioni D, Lencioni R, Rossi S et al (2001) Radiofrequency thermal ablation of hepatocellular carcinoma: using contrast-enhanced harmonic power Doppler sonography to assess treatment outcome. AJR Am J Roentgenol 177:783–788PubMed

10.

Cedrone A, Pompili M, Sallustio G, Lorenzelli GP, Gasbarrini G, Rapaccini GL (2001) Comparison between color power Doppler ultrasound with echo-enhancer and spiral computed tomography in the evaluation of hepatocellular carcinoma vascularization before and after ablation procedures. Am J Gastroenterol 96:1854–1859PubMedCrossRef

11.

Choi D, Lim HK, Kim SH et al (2002) Assessment of therapeutic response in hepatocellular carcinoma treated with percutaneous radio frequency ablation: comparison of multiphase helical computed tomography and power Doppler ultrasonography with a microbubble contrast agent. J Ultrasound Med 21:391–401PubMed

12.

Numata K, Isozaki T, Ozawa Y, Sakaguchi T, Kiba T, Kubota T et al (2003) Percutaneous ablation therapy guided by contrast-enhanced sonography for patients with hepatocellular carcinoma. AJR Am J Roentgenol 180:143–149PubMed

13.

Wen YL, Kudo M, Zheng RQ et al (2003) Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. AJR Am J Roentgenol 181:57–63PubMed

14.

Shimizu M, Iijima H, Horibe T et al (2004) Usefulness of contrast-enhanced ultrasonography with a new contrast mode, Agent detection imaging, in evaluating therapeutic response in hepatocellular carcinoma treated with radio-frequency ablation therapy. Hepatol Res 29:235–242PubMedCrossRef

15.

Vilana R, Llovet JM, Bianchi L et al (2003) Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. J Clin Ultrasound 31:119–128PubMedCrossRef

16.

Schneider M, Arditi M, Barrau MB et al (1995) BR1: a new ultrasonographic contrast agent based on sulfur -hexafluoride- filled microbubbles. Invest Radiol 30:451–457PubMedCrossRef

17.

Morel DR, Schwieger I,Hohn L, Terrettaz J, Llull JB, Cornioley YA et al (2000) Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. Invest Radiol 35:80–85PubMedCrossRef

18.

Sala M, Llovet JM, Vilana R et al (2004) Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40:1352–1360PubMedCrossRef

19.

Wilson SR, Burns PN, Murdali D et al (2000) Harmonic hepatic US with microbubbles contrast agent: initial experience showing improved characterisation of haemangioma, hepatocellular carcinoma and metastasis. Radiology 215:153–161PubMed

20.

Leen E, Angerson WJ, Yarmenitis S et al (2002) Multi-centre clinical study evaluating the efficacy of SonoVue (BR1), a new ultrasound contrast agent in Doppler investigation of focal hepatic lesions. Eur J Radiol 41:200–206PubMedCrossRef

21.

Basilico R, Blomley MJ, Harvey CJ et al (2002) Wich continuous US scanning mode is optimal for the detection of vascularity in liver lesions when enhanced with a second generation contrast agent? Eur J Radiol 41:184–191PubMedCrossRef

22.

Gaiani S, Celli N, Piscaglia F et al (2004) Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol 41:421–426PubMedCrossRef

23.

Nicolau C, Catala V, Vilana R et al (2004) Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent. Correlation with cellular differentiation. Eur Radiol 14:1092–1099PubMedCrossRef

24.

von Hervay A, Vogt C, Willers R, Haussinger D (2004) Real-time imaging with the sonographic contrast agent SonoVue : differentiation between benign and malignant hepatic lesions. J Ultrasound Med 23:1557–1568

25.

Giorgio A, Ferraioli G, Tarantino L et al (2004) Contrast - enhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: comparison with contrast-enhanced helical CT appearance. AJR Am J Roentgenol 183:1319–1326PubMed

26.

Ricci P, laghi A, Cantisani V et al (2005) Contrast-enhanced sonography with SonoVue : enhancement patterns of benign focal liver lesions and correlation with dynamic gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol 184:821–827PubMed

27.

Pasamonti M, Vercelli A, Azzaretti A, Rodolico G, Calliada F (2005) Characterización of focal liver lesions with a new ultrasound contrast agent using continuos low acoustic power imaging: comparison with contrast enhanced spiral CT. Radiol Med 109:358–369

28.

Bartolotta TV, Midiri M, Quaia E et al (2005) Benign focal liver lesions: spectrum of findings on SonoVue-enhanced pulse-inversion ultrasonography. Eur Radiol 15:1643–1649PubMedCrossRef

29.

Krix M, Plathow C, Essig M et al (2005) Monitoring of liver metastases after stereotactic radiotherapy using low-MI contrast-enhanced ultrasound-initial results. Eur Radiol 15:677–684PubMedCrossRef

30.

Solbiati L, Ierace T, Tonolini M, Cova L (2004) Guidance and monitoring of radiofrequency liver tumor with contrast-enhanced ultrasound. Eur Radiol 51(Suppl):S19–S23

31.

Solbiati L, Tonolini M, Cova L (2004) Monitoring RF ablation. Eur Radiol 14:34–42CrossRef

32.

Pompili M, Riccardi L, Covino M et al (2005) Contrast-enhanced gray-scale harmonic ultrasound in the efficacy assessment of ablation treatments for hepatocellular carcinoma. Liver international 25:954–961PubMedCrossRef

33.

Colagrande S, La Villa G, Batolucci M, Lanini F, Barletta G, Villari N (2003) Spiral computed tomography versus ultrasound in the follow-up of cirrhotic patients previously treated for hepatocellular carcinoma: a prospective study. J Hepatol 39:93–98PubMedCrossRef

Titel: Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?
verfasst von: R. Vilana
L. Bianchi
M. Varela
C. Nicolau
M. Sánchez
C. Ayuso
M. García
M. Sala
J. M. Llovet
J. Bruix
C. Bru
BCLC Group
Publikationsdatum: 01.11.2006
Verlag: Springer-Verlag
Erschienen in: European Radiology / Ausgabe 11/2006
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-006-0264-8

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?

Abstract

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2006

Three-dimensional MDCT imaging and CT esophagography for evaluation of esophageal tumors: preliminary study

Comparison of fundamental sonography, tissue-harmonic sonography, fundamental compound sonography, and tissue-harmonic compound sonography for focal hepatic lesions

Dose comparison between screen/film and full-field digital mammography

Dosimetric characteristics of a 16-slice computed tomography scanner

New coil concept for endoluminal MR imaging

Detection and characterization of benign focal liver lesions with multislice CT

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie